Brokerages expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report sales of $8.46 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for BioDelivery Sciences International’s earnings, with the lowest sales estimate coming in at $7.48 million and the highest estimate coming in at $11.00 million. BioDelivery Sciences International posted sales of $5.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 69.2%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year sales of $8.46 million for the current year, with estimates ranging from $53.09 million to $68.00 million. For the next year, analysts anticipate that the firm will post sales of $48.39 million per share, with estimates ranging from $43.06 million to $54.07 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.49. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%. The firm had revenue of $29.48 million for the quarter, compared to the consensus estimate of $27.07 million.

Several equities analysts recently weighed in on BDSI shares. Janney Montgomery Scott raised their target price on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research note on Monday. ValuEngine cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, July 12th. HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday. Finally, Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Tuesday, May 16th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.00.

BioDelivery Sciences International (NASDAQ:BDSI) opened at 3.35 on Thursday. The stock’s market capitalization is $185.34 million. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.60. The company’s 50-day moving average is $2.77 and its 200-day moving average is $2.15.

ILLEGAL ACTIVITY NOTICE: “BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Expected to Post Quarterly Sales of $8.46 Million” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/27/biodelivery-sciences-international-inc-nasdaqbdsi-expected-to-post-quarterly-sales-of-8-46-million.html.

A number of large investors have recently made changes to their positions in BDSI. GSA Capital Partners LLP acquired a new stake in shares of BioDelivery Sciences International during the fourth quarter valued at about $142,000. Searle & CO. increased its stake in shares of BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock valued at $410,000 after buying an additional 49,850 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its stake in shares of BioDelivery Sciences International by 5.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock valued at $1,913,000 after buying an additional 56,550 shares in the last quarter. Blair William & Co. IL increased its stake in shares of BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock valued at $1,386,000 after buying an additional 189,484 shares in the last quarter. Finally, NEXT Financial Group Inc increased its stake in shares of BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 4,000 shares in the last quarter. 40.33% of the stock is owned by institutional investors and hedge funds.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.